Abstract
Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, have addressed many of the existing shortcomings in the DAA therapy spectrum. This combination has proven to be a highly efficacious pan-genotypic DAA with a high barrier to resistance as a once-daily, all-oral medication. This review explores the design and development of glecaprevir and pibrentasvir, its place in current HCV management in the midst of a myriad of DAA therapy options, and also remaining challenges.
Keywords:
direct-acting antiviral therapy; glecaprevir; hepatitis C virus; pibrentasvir.
MeSH terms
-
Aminoisobutyric Acids
-
Antiviral Agents / chemical synthesis
-
Antiviral Agents / chemistry
-
Antiviral Agents / pharmacology*
-
Benzimidazoles / chemical synthesis
-
Benzimidazoles / chemistry
-
Benzimidazoles / pharmacology*
-
Cyclopropanes
-
Drug Design*
-
Hepacivirus / drug effects*
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Lactams, Macrocyclic
-
Leucine / analogs & derivatives
-
Microbial Sensitivity Tests
-
Molecular Conformation
-
Proline / analogs & derivatives
-
Pyrrolidines
-
Quinoxalines / chemical synthesis
-
Quinoxalines / chemistry
-
Quinoxalines / pharmacology*
-
Sulfonamides / chemical synthesis
-
Sulfonamides / chemistry
-
Sulfonamides / pharmacology*
Substances
-
Aminoisobutyric Acids
-
Antiviral Agents
-
Benzimidazoles
-
Cyclopropanes
-
Lactams, Macrocyclic
-
Pyrrolidines
-
Quinoxalines
-
Sulfonamides
-
pibrentasvir
-
Proline
-
Leucine
-
glecaprevir